세계의 뇌성 마비 치료 시장(2023-2030년)

Market Overview

The global cerebral palsy treatment market reached US$ 3,207.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,280.5 million by 2030. The global cerebral palsy treatment market is expected to exhibit a CAGR of 3.7% during the forecast period (2023-2030). The key players are adopting strategies such as partnerships, mergers, acquisitions, and regional expansion to stand out as strong competitors in the cerebral palsy treatment market. Novel product launches and enhanced focus on research and development are some of the other ways where the leading players can improve their market presence.

For instance, on August 31, 2021, the use of XEOMIN for the relief of symptoms of chronic sialorrhea caused by neurological or neurodevelopmental disorders in children and adolescents weighing less than 12 kg has been approved on an EU level for Merz Therapeutics, a division of the Merz Group and a pioneer in the field of neurotoxins.

Cerebral Palsy (CP) is a collection of non-progressive, chronic illnesses marked by stiffness and mobility disability. It arises when the brain does not develop normally in the womb or due to a post-natal injury. It can affect motor function in all four limbs, resulting in balance issues, muscular contracture, coordination issues, and other neurological symptoms.

The most common cerebral palsy is spastic, ataxic dyskinetic, and mixed. Treatment options include medications, therapies, surgical procedures, and other treatments to improve daily functioning. There is no cure for cerebral palsy.

Furthermore, the increasing prevalence of cerebral palsy disorder, rapid clinical trials, and increasing government funding and company investments are key factors expected to drive the market growth over the forecast period.

Market Dynamics

The increasing prevalence of premature births is boosting the global cerebral palsy treatment market growth

Premature birth, low birth weight, multiple childbirths, and infectious diseases during pregnancy can lead to a rise in cerebral palsy cases. An estimated 15 million babies are born prematurely yearly, with more than one out of every ten falling under this category. Every year, over one million children die due to premature birth complications. Many survivors may face obstacles for the rest of their life, such as learning disabilities and visual and hearing problems.

Moreover, health problems in the mother, such as thyroid illness, seizures, intellectual impairment, and so on, might induce cerebral palsy in the kid. In addition, the rapid growth of the cerebral palsy treatment market can be attributed to an increase in the incidence of cerebral palsy and an increase in parental awareness of cerebral palsy complications, and the availability of various treatment options in the market.

For instance, according to the Centres for Disease Control and Prevention, 1.5 to 4 children out of every 1000 in the United States have cerebral palsy. The condition is caused by aberrant development or injury to brain regions that govern movement, posture, and balance. Cerebral palsy is most frequent before birth, but difficulties can arise during or immediately after birth. Thus, from the above factors, the cerebral palsy treatment market is expected to drive over the forecast period.

Acute side effects due to medications are hampering the growth of the global cerebral palsy treatment market

Medications are an important part of cerebral palsy treatment, helping to manage symptoms and improve quality of life, but can also have side effects. For instance, muscle relaxants can cause drowsiness and fatigue, which can affect a patient's ability to perform daily activities and interfere with their school or work.

Similarly, antispasmodics can cause gastrointestinal disturbances when used to treat cerebral palsy, such as constipation, diarrhea, and bloating. Hence, owing to the above factors, the cerebral palsy treatment market is expected to be hampered over the forecast period.

COVID-19 Impact Analysis

COVID-19 has had a significant impact on the cerebral palsy treatment market. Healthcare facilities have prioritized COVID-19 patients, leading to delays or cancellations of non-emergency treatments. The pandemic has caused reduced access to healthcare services, making it more difficult for patients with cerebral palsy to access the care they need.

Moreover, the pandemic has disrupted supply chains for medications and medical equipment, making it more difficult for healthcare providers to treat patients with cerebral palsy. Likewise, it had a sign on the development, production, and distribution of drugs used to treat cerebral palsy, including delayed clinical trials.

In contrast, telemedicine services have become increasingly popular due to the difficulty of visiting healthcare facilities in person, but it is not always a substitute for in-person care for patients with cerebral palsy.

Russia-Ukraine Conflict Analysis

Russia's invasion of Ukraine has caused a humanitarian crisis, disproportionately impacting people with intellectual disabilities and their families. Children in orphanages with disabilities had become twisted and constricted due to lack of activity and treatment for spastic cerebral palsy, so charitable organizations provided regular treatments to reduce pain. Similarly, global fund for Children partners in Ukraine is helping children with disabilities and their families evacuate to safer areas and get essential supplies. Therefore, the conflict has had a moderate impact on the global cerebral palsy treatment market.

Artificial Intelligence Impact Analysis

AI systems help to refine prognosis and assist in management selection for children with cerebral palsy. For instance, researchers at Stanford and Gillette Children's Specialty Hospital in Minnesota have used artificial intelligence and video shot with a single camera to analyze movement impairment in people diagnosed with cerebral palsy. This system is inexpensive, easy to use, and open-source, allowing doctors to better identify, measure progress, and treat neurological and musculoskeletal disorders.

Segment Analysis

The global cerebral palsy treatment market is segmented based on drug type, disease type, distribution channel, and region.

The spastic cerebral palsy segment is expected to hold a dominant position in the market over the forecast period

The spastic cerebral palsy segment accounted for the highest market stake accounting for approximately 70.4% of the cerebral palsy treatment market in 2022. Spastic cerebral palsy is a developmental disorder caused by brain damage before birth, during delivery, or in the first few years of life. Children are the most affected and develop co-occurring symptoms, driving revenue growth in this segment.

Spastic CP, such as quadriplegia, hemiplegia, and diplegia, affects the body the most. Treatment options such as physical therapy, medication, baclofen pump, spine or cord surgery, muscle release, and tendon lengthening surgery are used to prevent symptoms, creating demand for this segment.

Moreover, companies such as Merz Pharmaceuticals, Teva Pharmaceuticals, Supernus Pharmaceuticals, and Rohto Pharmaceutical are conducting clinical trials to explore new treatment options, driving revenue growth.

Geographical Analysis

The increasing prevalence of cerebral palsy disorder, and increasing funding by government organizations to dominate the North America region

North America is expected to dominate the worldwide cerebral palsy treatment market, accounting for around 2/5th of this market, with the U.S. being the major contributor. For instance, the U.S. government offers a variety of financial benefits to people with cerebral palsy, such as benefit programs, scholarships, grants, and subsidized loans. The most common resources are Supplemental Security Income (SSI), the Individuals With Disabilities Education Act (IDEA), and Medicaid.

Competitive Landscape

The major global players in the market include Merz Pharmaceuticals, LLC., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical, and Hikma Pharmaceuticals Plc among others.

Why Purchase the Report?

• To visualize the global cerebral palsy treatment market segmentation based on the drug type, disease type, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cerebral palsy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global cerebral palsy treatment market report would provide approximately 61 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Disease Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The increasing prevalence of premature births is boosting the global cerebral palsy treatment market growth during the forecast period.
  • 4.1.2. Restraints
    • 4.1.2.1. Acute side effects due to medications are hampering the growth of the global cerebral palsy treatment market in the forecast period.
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing collaborative research efforts
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Before COVID-19 Scenario
  • 6.1.2. Present COVID-19 Scenario
  • 6.1.3. Post COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Artificial Intelligence Impact Analysis

9. By Drug Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.1.2. Market Attractiveness Index, By Drug Type
• 9.2. Anticonvulsants*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Anticholinergics
• 9.4. Antidepressants
• 9.5. Other

10. By Disease Type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.1.2. Market Attractiveness Index, By Disease Type
• 10.2. Spastic Cerebral Palsy*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Mixed Cerebral Palsy
• 10.4. Dyskinetic Cerebral Palsy
• 10.5. Ataxic Cerebral Palsy

11. By Distribution Channel

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.1.2. Market Attractiveness Index, By Distribution Channel
• 11.2. Hospital Pharmacies*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Retail stores and Pharmacies
• 11.4. Online Pharmacies

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. The U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. The U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Merz Pharmaceuticals, LLC. *
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Pfizer Inc.
• 14.3. Viatris Inc.
• 14.4. Teva Pharmaceutical Industries Ltd.
• 14.5. F. Hoffmann-La Roche Ltd
• 14.6. GlaxoSmithKline plc.
• 14.7. Novartis
• 14.8. AbbVie Inc.
• 14.9. Par Pharmaceutical
• 14.10. Hikma Pharmaceuticals Plc.

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us